End‐of‐treatment MRD negativity showed a trend towards association with a better ORR (100% vs. 69%, p = 0.105) and CR rate (90% vs. 54%, p = 0.062; Table S9 ), a trend towards association with improved PFS (2‐year PFS 90% vs. 46%, HR 0.26, 95% CI 0.07–0.95, p = 0.065), and was significantly associated with a better OS (2‐year OS 100% vs. 69%, HR 0.15, 95% CI 0.03–0.85, p = 0.031; Figure 6C,D ).
3D ), while the expression level of Na v 1.6 showed a trend of reduction ( P = 0.105).
Anticoagulant use showed a trend (OR 1.81; 95% CI 0.88–3.69; p = 0.105), though not statistically significant.
A post hoc analysis showed a trend toward a treatment difference (−253 g/week [−563; 58] P = .105).
Daily mean leptin concentration showed a trend towards a moderately correlated positive linear relationship with rumen temperature ( p = 0.106, r = 0.613) for the FRTN group only (Fig. 5 E).
In the SRR cohort, sotrovimab showed a trend toward lower outcome risk than molnupiravir [HR 0.39 (95% CI 0.13–1.21); P = .106].
Upon progressive disease, 20 patients (30.8%) received subsequent chemotherapy, and showed a trend for longer median overall survival (OS) than in those receiving a non-chemotherapy regimen (25.0 vs. 11.8 months, p = 0.106).
Meta-regression showed a trend for greater DBP reduction with higher pretreatment DBP ( P = 0.106) ( Figure 2B ).
Similarly, a history of hallucinations or psychosis showed a trend in the same direction (11/19 [57.9%] vs. 5/17 [29.4%], p =0.106).
The latter showed a trend toward less edema (p = 0.106, Jonckheere-Terpstra) in patients >65 ys.
While not reaching statistical significance, individuals with acute COVID-19 showed a trend toward greater IMT increases (0.19 mm, 95% CI: 0.06–0.69) compared to those with non-acute disease (0.10 mm, 95% CI: 0.06–0.13, and p = 0.106).
The risk of POAF observed in the late postoperative period showed a trend toward increased risk that did not reach statistical significance (HR 1.25, 95% CI 0.95–1.64, p=0.106).
Although there were no statistical differences, Kaplan-Meier analyses showed a trend that RFS in patients with high serum FGF19 levels (≥200 pg/mL) is shorter than those in patients with low serum FGF19 levels ( p = 0.106, Fig. 5 a).
For TP53 wt CK-AML, STAT3 inhibitor (S31-201) was the only potent compound that showed a trend towards sensitivity ( P = 0.106) (Fig. 1B ).
The ZNS-treated α1β2γ2/γ2(Q390X) + pcDNA condition (ZNS) showed a trend towards an increase (0.572 ± 0.017), but this was not statistically different from Q390X ( p = 0.106) and was still lower than WT ( p < 0.0001) ( Figure 3 A,D).
Importantly, most physiological, functional, and psychological parameters showed no statistically significant baseline differences (all P>0.05); however, the intervention group showed a trend toward better baseline upper limb muscle tone scores (P = 0.106), suggesting a possible selection bias in patients with better functional status in the intervention group.
Hearts with TGA and Ebstein, although not reaching statistical significance, showed a trend to an increased risk of LVNC (TGA: p = 0.1064; OR 6.93; 95CI 0.38–126.1; Ebstein: p = 0.0711; OR 27.09; 95CI 0.49–189.2) when analyzed by Chin’s method. 3.5.
A Glasgow coma scale (GCS) of more than 3 showed a trend ( p =0.1065) toward a better motor functional outcome.
Indeed, the thickening fraction during tidal breathing showed a trend towards increased values during true acupuncture (43.5 ± 16.6%) vs. sham (31.3 ± 14.9%) and baseline (30.8 ± 15.3%), p =0.1066.
Combination of surgery and chemotherapy showed a trend towards higher overall survival in non-metastatic patients (p = 0.1069 and p = 0.1703).
However, the T-αFGL2 cells showed a trend toward enrichment in core T RM genes when compared with T-Ctr cells (Supplementary Fig. 8f , NES = 1.23, P = 0.107), suggesting that T-αFGL2 treatment does not directly transform regular T cells into brain tumor–specific T RM cells.
Carrier children showed a trend ( p = 0.107, two-tailed Mann-Whitney test) towards carrying a higher number of minor eQTLs alleles (average = 4.3/person) than their carrier parents (average = 3.2/person) (Additional file 1 : Fig.
Analysis of overall survival (OS) showed a trend towards shorter OS in the HR patient cohort (HR vs LR days, p = .107; Supplementary Fig.
CXCR4 expression significantly increased at recurrence ( p = 0.029), and expression of its ligand CXCL12 showed a trend toward an increase ( p = 0.107).
L-centres showed a trend towards superior R1 rate (CRM+ and/or DRM+) with 4.4% versus 8.7% in R-centres and 8.4% in Ta-centres, P = 0.107.